Loading
HBB (Haemoglobin subunit beta) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. This dossier gathers the 0 products (0 approved), 0 trials, 0 pathways and 0 resistance routes in the corpus that involve it, with external identifiers so it can be joined to UniProt, ChEMBL, Open Targets and the rest of biology.
Involved in oxygen transport from the lung to the various peripheral tissues. LVV-haemorphin-7 potentiates the activity of bradykinin, causing a decrease in blood pressure. Functions as an endogenous inhibitor of enkephalin-degrading enzymes such as DPP3, and as a selective antagonist of the P2RX3 receptor which is involved in pain signalling, these properties implicate it as a regulator of pain and inflammation. Locus 11p15.4 (HGNC).
No product in the corpus is aimed at this target yet.
No trial in the corpus names this target or one of its products.
No recorded escape route names this target.
No pathway diagram carries this target as a node.
No companion diagnostic in the registry measures this target.
No model entry for this target yet; check the cancer entries on the models page.
No open questions recorded for this target yet. Suggest one.
Query for this target: (TITLE:"HBB" OR ABSTRACT:"HBB" OR TITLE:"hemoglobin subunit beta" OR ABSTRACT:"hemoglobin subunit beta" OR TITLE:"Hemoglobin subunit beta" OR ABSTRACT:"Hemoglobin subunit beta" OR TITLE:"CD113t-C" OR ABSTRACT:"CD113t-C" OR TITLE:"beta-globin" OR ABSTRACT:"beta-globin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HBB, not a curated reading list.
The dossier as machine-readable JSON, at /api/v1/dossiers/hbb.json: identifiers from HGNC, Ensembl, UniProt and ChEMBL, products with status, trials, pathways, hotspots, open questions and assays. The full entity record is in the open API at /api/v1/entities/hbb.json. Licence CC BY-NC 4.0.